Skip to content
What if…

We were to view the microbiome not as a vast collection of different microbe species, but as a single organ with critical functions?

It turns out…

We can create and administer drugs targeting the microbiome as a whole, and potentially drive beneficial effects across a range of disease states and conditions (including diabetes, cardiovascular, liver, kidney, and infectious diseases).

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health.

Latest Press from Kaleido Biosciences